Our perspectives
in one place
Topic
Selected filters
ClearNews
See all76th WHO Regional Committee for Africa: Special update on the ongoing Ebola virus disease outbreak caused by Bundibugyo Virus
On 26 August, IFPMA delivered a statement on the special update on the ongoing Ebola virus disease outbreak caused by Bundibugyo Virus at the 76th session off the WHO Regional Committee for Africa in Addis Ababa. Marking the 100th day after the Bundibugyo outbreak was declared, the global pharmaceutical industry underscores its commitment and track...
Read more76th WHO Regional Committee for Africa: Regional strategy on regulation of medical products in the African region, 2026-2035
On 26 August 2026, IFPMA delivered a statement on the regional strategy on regulation of medical products in the African region, 2026-2035, during the 76th WHO Regional Committee for Africa in Addis Ababa, Ethiopia. IFPMA welcomes the proposed Strategy on Regulation of Medical Products, and commends WHO AFRO, Member States, and regional institutions for their...
Read moreAMATA Statement at WHO Regional Committee for Africa: Regional strategy on regulation of medical products in the African Region, 2026-2035
The members of the African Medicines Agency Treaty Alliance (AMATA) welcome and strongly support the Regional Strategy on Regulation of Medical Products in the African Region, 2026–2035. Access to safe, effective, quality-assured medical products depends on a strong regulatory system. However, a truly harmonized and effective regulatory system cannot be achieved without continental coordination and...
Read more76th WHO Regional Committee for Africa: Strategy for financing the future of health in the WHO African Region, 2026–2035
On 26 August 2026, IFPMA delivered a statement on a strategy for financing the future of health in the WHO African Region, 2026-2036, during the 76th WHO Regional Committee for Africa in Addis Ababa, Ethiopia. IFPMA welcomes the strategy for financing the future of health in the WHO African Region and its focus on sustainable,...
Read more76th WHO Regional Committee for Africa – A new era of health for Africa: United action for Vision 2035
On 25 August 2026, IFPMA delivered a statement on united action for Vision 2035 during the 76th WHO Regional Committee for Africa in Addis Ababa, Ethiopia. IFPMA welcomes the Vision 2035 strategy, including its emphasis on accelerating UHC, health systems resilience, digital transformation, health workforce and leadership transformation, and institutional modernization. Geographical diversification of manufacturing...
Read more100 Day milestone of Ebola Bundibugyo outbreak must be a “wake up call” for pandemic preparedness, says pharma industry
To mark the 100 days after the declaration of the Ebola Bundibugyo outbreak, IFPMA and BIO underline the global pharmaceutical industry’s record and commitment to tackling health emergencies.
Read morePublications
See allHealthy planet, healthy people: The innovative pharmaceutical industry’s contribution to the Kunming-Montreal Global Biodiversity Framework
Through company-level initiatives and decades of pre-competitive collaboration, IFPMA member companies are working to reduce environmental impact and contribute positively to a healthy and biodiverse planet.
Read more
International data flows: Enabling data-driven, patient-centric innovative pharmaceutical research and development (R&D)
To fulfill the potential of data and new technologies in supporting the shared objective of improving patient lives and population health, it is vital that well-designed systems are put in place.
Read more
Enabling innovation: The R&D ecosystem for medicines and vaccines
Decisive policy action is critical to sustain innovation that improves people’s lives. This position paper illustrates the R&D ecosystem in action, and underscores the importance of continued commitment by governments and across stakeholders to ensure the conditions that enable the development and delivery of transformative medicines and vaccines.
Read more
Expert insights
See all
Building pandemic readiness through routine vaccination
Read more
The G7 cannot afford to lose its leadership in pharmaceutical innovation
Read more
Innovative medicines as drivers of economic security – A strategic imperative for G7 economies
Read moreResources
See allAdult immunization for healthy workforces and healthy economies in an aging world
IFPMA and the Global Coalition on Ageing (GCOA) outline why vaccination is essential to building healthier workforces and stronger economies in an aging world.
Read more
Streamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more